{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:35:50Z","timestamp":1793414150120,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Heath Research Foundation of Chinese Society of Clinical Oncology","award":["Y-2019Genecast-024"],"award-info":[{"award-number":["Y-2019Genecast-024"]}],"id":[{"id":"https:\/\/ror.org\/05sfnze82","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2021JJ30430"],"award-info":[{"award-number":["2021JJ30430"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Project of Health and Health Commission of Hunan Province","award":["20201566"],"award-info":[{"award-number":["20201566"]}]},{"name":"Hunan Cancer Hospital Climb Plan","award":["ZX2020005-5 and YF2020005"],"award-info":[{"award-number":["ZX2020005-5 and YF2020005"]}],"id":[{"id":"https:\/\/ror.org\/025020z88","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-XD202001-0215"],"award-info":[{"award-number":["Y-XD202001-0215"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the science and technology innovation Program of Hunan Province","award":["2023SK4024"],"award-info":[{"award-number":["2023SK4024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      About 10% of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (\n                      <jats:italic>EGFR<\/jats:italic>\n                      ) mutations are harbored as uncommon mutations. This study aimed to explore the efficacy and safety of dacomitinib, a second-generation\n                      <jats:italic>EGFR<\/jats:italic>\n                      tyrosine kinase inhibitor (EGFR-TKIs), in treating uncommon\n                      <jats:italic>EGFR<\/jats:italic>\n                      -mutated advanced NSCLC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Treatment-na\u00efve advanced NSCLC patients treated with dacomitinib at Hunan Cancer Hospital with uncommon\n                      <jats:italic>EGFR<\/jats:italic>\n                      mutations were evaluated. The primary endpoint was progression-free survival (PFS). Secondary end points included overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Between December 2019 and December 2021, a total of 16 patients was included. Median PFS was 14.0 (95% CI 4.32\u201323.7) months, and median OS was not reached. ORR was 68.8% (95% CI 41.3 to 89.0%) and DCR was 93.8% (95%CI 69.8 to 99.8%), including three achieving complete remission (CR) and eight achieving partial remission (PR). Median PFS for patients with brain metastasis was 9.0 (95%CI 6.9 to 11.1) months. Intracranial ORR was 100%, including 2 CR and 4 PR. Major treatment-related adverse events (TRAEs) included rash (87.5%), paronychia (62.5%), oral ulcers (50.0%), and diarrhea (50.0%), none of which were\u2009\u2265\u2009grade 3 TRAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Dacomitinib showed good activity and manageable toxicity in NSCLC patients with uncommon\n                      <jats:italic>EGFR<\/jats:italic>\n                      mutations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-023-11465-2","type":"journal-article","created":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T21:02:06Z","timestamp":1697403726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of dacomitinib in treatment-na\u00efve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Xingxiang","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aifang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"issue":"3","key":"11465_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"11465_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39\u201351.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"11465_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","volume":"16","author":"A Passaro","year":"2021","unstructured":"Passaro A, Mok T, Peters S, Popat S, Ahn M-J, de Marinis F. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions. EGFR Mutations J Thorac Oncol. 2021;16(5):764\u201373.","journal-title":"EGFR Mutations J Thorac Oncol"},{"issue":"1","key":"11465_CR4","first-page":"36","volume":"4","author":"BA Chan","year":"2015","unstructured":"Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36\u201354.","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"11465_CR5","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1093\/annonc\/mdx404","volume":"28","author":"C Leduc","year":"2017","unstructured":"Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol. 2017;28(11):2715\u201324.","journal-title":"Ann Oncol"},{"issue":"2","key":"11465_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"11","key":"11465_CR7","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454\u201366.","journal-title":"Lancet Oncol"},{"key":"11465_CR8","doi-asserted-by":"crossref","unstructured":"Wu S-G, Yu C-J, Yang JC-H, Shih J-Y. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Ther Adv Med Oncol. 2020;12:1758835920946156.","DOI":"10.1177\/1758835920946156"},{"key":"11465_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101994","volume":"85","author":"V Gristina","year":"2020","unstructured":"Gristina V, Malapelle U, Galvano A, Pisapia P, Pepe F, Rolfo C, et al. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. Cancer Treat Rev. 2020;85: 101994.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"11465_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","volume":"15","author":"JC Yang","year":"2020","unstructured":"Yang JC, Schuler M, Popat S, Miura S, Heeke S, Park K, et al. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020;15(5):803\u201315.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"11465_CR11","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1158\/1078-0432.CCR-10-1220","volume":"17","author":"PA J\u00e4nne","year":"2011","unstructured":"J\u00e4nne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011;17(5):1131\u20139.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"11465_CR12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/cncr.28561","volume":"120","author":"KL Reckamp","year":"2014","unstructured":"Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, Khuri FR, Engelman JA, et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 2014;120(8):1145\u201354.","journal-title":"Cancer"},{"key":"11465_CR13","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"11465_CR14","doi-asserted-by":"crossref","unstructured":"Wu J-Y, Yu C-J, Chang Y-C, Yang C-H, Shih J-Y, Yang P-C. Effectiveness of tyrosine kinase inhibitors on \u201cuncommon\u201d epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011;17(11):3812\u201321.","DOI":"10.1158\/1078-0432.CCR-10-3408"},{"issue":"2","key":"11465_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/JTO.0000000000000048","volume":"9","author":"S Watanabe","year":"2014","unstructured":"Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, et al. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014;9(2):189\u201394.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"11465_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.lungcan.2014.11.013","volume":"87","author":"JH Baek","year":"2015","unstructured":"Baek JH, Sun J-M, Min YJ, Cho EK, Cho BC, Kim J-H, et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. Lung Cancer. 2015;87(2):148\u201354.","journal-title":"Lung Cancer"},{"issue":"5","key":"11465_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","volume":"10","author":"C-H Chiu","year":"2015","unstructured":"Chiu C-H, Yang C-T, Shih J-Y, Huang M-S, Su W-C, Lai R-S, et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X\/L861Q\/S768I Mutations. J Thorac Oncol. 2015;10(5):793\u20139.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"11465_CR18","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/bjc.2016.372","volume":"115","author":"JL Kuiper","year":"2016","unstructured":"Kuiper JL, Hashemi SMS, Thunnissen E, Snijders PJF, Gr\u00fcnberg K, Bloemena E, et al. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br J Cancer. 2016;115(12):1504\u201312.","journal-title":"Br J Cancer"},{"issue":"6","key":"11465_CR19","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.3892\/ol.2017.5980","volume":"13","author":"P Krawczyk","year":"2017","unstructured":"Krawczyk P, Kowalski DM, Ramlau R, Kalinka-Warzocha E, Winiarczyk K, Stencel K, et al. Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare gene mutations. Oncol Lett. 2017;13(6):4433\u201344.","journal-title":"Oncol Lett"},{"key":"11465_CR20","doi-asserted-by":"crossref","unstructured":"Pilotto S, Rossi A, Vaval\u00e0 T, Follador A, Tiseo M, Galetta D, et al. Outcomes of first-generation EGFR-TKIs against non-small-cell lung cancer harboring uncommon EGFR mutations: a post Hoc analysis of the BE-POSITIVE study. Clin Lung Cancer. 2018;19(1):93\u2013104.","DOI":"10.1016\/j.cllc.2017.05.016"},{"key":"11465_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.lungcan.2022.08.010","volume":"172","author":"C Wang","year":"2022","unstructured":"Wang C, Zhao K, Hu S, Dong W, Gong Y, Li M, et al. Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients. Lung cancer (Amsterdam, Netherlands). 2022;172:86\u201393.","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"7","key":"11465_CR22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","volume":"16","author":"JCH Yang","year":"2015","unstructured":"Yang JCH, Sequist LV, Geater SL, Tsai C-M, Mok TSK, Schuler M, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830\u20138.","journal-title":"Lancet Oncol"},{"issue":"12","key":"11465_CR23","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.tips.2019.10.004","volume":"40","author":"S Guardiola","year":"2019","unstructured":"Guardiola S, Varese M, S\u00e1nchez-Navarro M, Giralt E. A Third Shot at EGFR: New Opportunities in Cancer Therapy. Trends Pharmacol Sci. 2019;40(12):941\u201355.","journal-title":"Trends Pharmacol Sci"},{"key":"11465_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.919652","volume":"13","author":"HS Li","year":"2022","unstructured":"Li HS, Yang GJ, Cai Y, Li JL, Xu HY, Zhang T, et al. Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China. Front Pharmacol. 2022;13: 919652.","journal-title":"Front Pharmacol"},{"issue":"5","key":"11465_CR25","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.19.00931","volume":"38","author":"JH Cho","year":"2020","unstructured":"Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, et al. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J Clin Oncol. 2020;38(5):488\u201395.","journal-title":"J Clin Oncol"},{"issue":"2","key":"11465_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jtho.2022.10.004","volume":"18","author":"J Bar","year":"2023","unstructured":"Bar J, Peled N, Schokrpur S, Wolner M, Rotem O, Girard N, et al. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN). J Thorac Oncol. 2023;18(2):169\u201380.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"11465_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000262","volume":"3","author":"M Preusser","year":"2018","unstructured":"Preusser M, Winkler F, Valiente M, Manegold C, Moyal E, Widhalm G, et al. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO open. 2018;3(1): e000262.","journal-title":"ESMO open"},{"issue":"5","key":"11465_CR28","doi-asserted-by":"publisher","first-page":"5897","DOI":"10.21037\/apm-20-2556","volume":"10","author":"C-G Shan","year":"2021","unstructured":"Shan C-G, Wang H, Lin T, Liu D, Wen L, Chen Z-J, et al. A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report. Ann Palliat Med. 2021;10(5):5897\u2013901.","journal-title":"Ann Palliat Med"},{"key":"11465_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fonc.2020.00224","volume":"10","author":"C Ma","year":"2020","unstructured":"Ma C, Zhang J, Tang D, Ye X, Li J, Mu N, et al. Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations. Front Oncol. 2020;10:224.","journal-title":"Front Oncol"},{"key":"11465_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.lungcan.2020.12.008","volume":"152","author":"W Peng","year":"2021","unstructured":"Peng W, Pu X, Jiang M, Wang J, Li J, Li K, et al. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report. Lung Cancer. 2021;152:66\u201370.","journal-title":"Lung Cancer"},{"issue":"24","key":"11465_CR31","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1111\/1759-7714.14222","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang J, Wang Y, Liu Z, Wang L, Yao Y, Liu Y, et al. Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. Thorac Cancer. 2021;12(24):3407\u201315.","journal-title":"Thorac Cancer"},{"issue":"1","key":"11465_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/1759-7714.13712","volume":"12","author":"S Mizusaki","year":"2021","unstructured":"Mizusaki S, Otsubo K, Ninomiya T, Arimura H, Tsuchiya-Kawano Y, Inoue K. Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR-mutant non-small cell lung cancer. Thorac Cancer. 2021;12(1):114\u20136.","journal-title":"Thorac Cancer"},{"issue":"14","key":"11465_CR33","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.2169\/internalmedicine.4449-20","volume":"59","author":"K Kudo","year":"2020","unstructured":"Kudo K, Kawakado K, Kawajiri T, Nishi T, Makimoto G, Tamura T, et al. Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib. Intern Med. 2020;59(14):1739\u201340.","journal-title":"Intern Med"},{"key":"11465_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.919652","volume":"13","author":"H-S Li","year":"2022","unstructured":"Li H-S, Yang G-J, Cai Y, Li J-L, Xu H-Y, Zhang T, et al. Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China. Front Pharmacol. 2022;13: 919652.","journal-title":"Front Pharmacol"},{"issue":"9","key":"11465_CR35","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.21037\/jtd-19-3790","volume":"12","author":"A Brindel","year":"2020","unstructured":"Brindel A, Althakfi W, Barritault M, Watkin E, Maury JM, Bringuier PP, et al. Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors. J Thorac Dis. 2020;12(9):4643\u201350.","journal-title":"J Thorac Dis"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11465-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-11465-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11465-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T19:14:12Z","timestamp":1700421252000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-11465-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["11465"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-11465-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"2 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Hunan Cancer Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"982"}}